Roche has reported a 5 percent rise in sales for the first quarter of 2013, boosted by strong demand for Tamiflu
Total sales hit 11.6 billionn Swiss francs ($12.4 billion) in the first three months of 2013.
Tamiflu sales rose during a heavy flu season in the US, and there was also strong demand for Roche’s cancer drugs.
“We got off to a very good start in 2013 due to strong organic growth,” said Roche chief executive Severin Schwan.
During the first quarter of 2013, the Basel-based company launched two new drugs to fight breast cancer, Kadcyla in the US and Perjeta in Europe.
Roche expects its full-year total sales to grow at much the same rate as 2012, when they rose by 7%. Roche also said it expected to increase its share dividend this year.
“Based on the first quarter results, I am confident we will meet our full-year targets,” Severin Schwan said.
The US House Ethics Committee has voted to release its report on former Republican Representative…
ABC News has agreed to pay $15 million to President-elect Donald Trump to settle a…
South Korea’s parliament has voted to impeach President Yoon Suk Yeol over his failed attempt…
Israeli war planes have carried out more than 100 air strikes in Syria on December…
President-elect Donald Trump has threatened to impose 100% tariffs on the BRICS countries if they…
Syrian troops have withdrawn from the city of Aleppo following an offensive by rebels opposed…
